Gemfibrozil Capsules

Blood lipid regulator, animal experiments show that this product can significantly inhibit serum triglycerides and serum total cholesterol in hyperlipidemia rats and normal rats, increase high-density lipoprotein cholesterol, and help inhibit the process of atherosclerosis. Clinical studies have shown that this product can reduce triglycerides, serum total cholesterol and low-density lipoprotein cholesterol, and increase high-density lipoprotein cholesterol. Studies have shown that this product can reduce the risk of death from coronary heart disease. Side effects are relatively small.

Gemfibrozil

Capsules. Contains white crystalline powder.

Suitable for primary hyperlipidemia.

Oral administration: 0.6g at a time, 1.2g per day, half an hour before breakfast and dinner, or as directed by a doctor.

The main adverse reactions are gastrointestinal reactions, such as diarrhea, decreased appetite, occasional dizziness, elevated serum alanine aminotransferase in some patients, and occasional rash. There are no serious adverse reactions.

Not yet clear

Precautions for children: There is insufficient research on the use of this product in children, so the pros and cons must be weighed when using it. Precautions for pregnancy and lactation: High doses of this product can cause fetal death in animals, but no human studies have been reported. It is unknown whether this product enters breast milk, so pregnant and lactating women should not take this product.

Not yet clear

seal

0.3 g

36 months

Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.

• Founded in:

  1998-05-26

• Address:

  No. 1, Jinlong East Road, Hetang District, Zhuzhou City, Hunan Province

• Tax NO.:

  9143020071210238X7

• Registered Funds:

  48 million yuan

• Website:

  Log in to view

• Email:

  Log in to view